| Literature DB >> 32189935 |
Waseem Amjad1, Sandy Kotiah2, Ankur Gupta3, Michael Morris3, Li Liu4, Paul J Thuluvath1,5.
Abstract
The use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected because cytotoxic T-lymphocyte-associated protein-4 and programmed death 1 pathways are implicated in graft tolerance. In this case report, we describe a woman with recurrent, disseminated hepatocellular carcinoma who was successfully treated with nivolumab, an immune checkpoint inhibitor.Entities:
Keywords: CPI, immune checkpoint inhibitor; HCC, Hepatocellular carcinoma; PD- L1, programmed death -ligand 1; PD-1, programmed death -1; immune checkpoint inhibitor; post liver transplant; recurrent HCC
Year: 2019 PMID： 32189935 PMCID： PMC7067990 DOI： 10.1016/j.jceh.2019.11.009
Source DB: PubMed Journal: J Clin Exp Hepatol ISSN： 0973-6883